Astellas Americas has a new VP in its Medical Affairs Oncology therapeutic area, and a new VP and an executive director of promotions in its corporate communications organization.

Jason D. Hanson was appointed president, CEO and director of enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs.

Thane Wettig was appointed to the newly created role of chief marketing officer and metabolic franchise head at Intarcia Therapeutics Inc.

Richard Klinghoffer, Ph.D., was named CEO of Presage Biosciences.

Genesis Drug Discovery & Development appointed Olesia Buiakova, M.D., Ph.D., as chief scientific officer.

Merck & Co. plans to move its European clinical operations to central London and bring in 150 new scientists and 800 additional staff.

During a meeting with President Donald Trump, Amgen CEO Robert Bradway told the president the company will be hiring 1,600 people across the United States in 2017.

Merck has opened a new Exploratory Science Center in Cambridge, Mass. The cutting-edge facility will focus on early discovery research.

May 2, 2016By Mark Terry, Breaking News Staff   EMD Serono announced today that it was building a $12 million expansion of its research-and-development facility in Billerica, Mass. EMD Serono is the U.S. subsidiary of Darmstadt, Germany-based Merck KgaA (MRK). The expansion will add 30,000 square feet to the existing space at the Sagamore […]

Mark Enyedy, a former executive vice president at Shire Plc , will take over ImmunoGen Inc. as the company’s next president and chief executive officer.